Implications for pharma marketers and consumers: The removal of suicide warnings helps pharma marketers position GLP-1 therapies as safe, mainstream therapies for chronic conditions, just as new oral options are expected expand the market
MT-2's systemic activity makes this particularly important
Weight loss in response to chronic semaglutide treatment can be divided into distinct phases, and each phase is characterized by different effects on food intake, meal patterns, energy expenditure, and substrate oxidation
We're excited to see the community engaging with this new NPF Medical Board Primer
Huell M, Strauss S, Volk B, Berger M, Bauer J (1995) Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimers disease patients